Colgate Q2 Earnings: Do Productivity Initiatives Suggest a Beat?

Colgate-Palmolive (CL) is forecast to report a 2.2% year-over-year EPS decline to $0.89 on largely flat Q2 2025 revenues of $5.1 billion, despite benefits from productivity initiatives and pricing gains. The company's performance is expected to be significantly impacted by persistent inflationary pressures, foreign currency headwinds, and soft North American sales, contributing to a projected 0.3% overall sales decline. While management's efforts aim for gross margin expansion, the Zacks model does not conclusively predict an earnings beat, and CL's shares, which have underperformed the industry, trade at a relatively high forward P/E of 22.71x.

Analysis

Colgate-Palmolive (CL) faces a challenging outlook for its second-quarter 2025 earnings report, with consensus estimates pointing to a 2.2% year-over-year decline in EPS to $0.89 on effectively flat revenue of $5.1 billion. While the company's productivity programs, pricing power, and innovation are expected to support sequential gross margin expansion, these positives are likely to be counteracted by significant headwinds. Key concerns include persistent inflationary pressures, adverse foreign currency fluctuations eroding reported sales, and notable weakness in major geographic segments. Specifically, sales are projected to decline by 3% in North America and 1% in Latin America, indicating challenges in maintaining pricing power amid competitive activity. The composition of expected growth is also a concern, with a minimal 0.2% volume increase being heavily outweighed by a 2.1% pricing gain, suggesting weak underlying consumer demand. Reinforcing this cautious view, the Zacks model does not predict an earnings beat, citing a negative Earnings ESP of -0.11%. The stock has already underperformed its industry by 1.8 percentage points over the last three months and trades at a premium forward P/E multiple of 22.71x, above the industry average of 19.97x.

Key Decisions for Investors

• A cautious stance is warranted ahead of the earnings release, given the combination of a projected EPS decline, a proprietary model that does not predict a beat, and significant regional and currency headwinds.
• Investors should scrutinize the upcoming report for the performance in North America and the gross margin impact from pricing initiatives, as these will be key indicators of the company's ability to navigate competitive and inflationary pressures.
• Given the stock's premium valuation at a 22.71x forward P/E and its recent underperformance, the risk/reward profile appears unfavorable, suggesting investors might evaluate the relative strength of peers that the report notes have a better setup for an earnings beat.